Kintara Therapeutics

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO , March 10, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces its participation in two upcoming conferences. 35th Annual ROTH Conference, March 12-14, 2023 – Dana Point, CA Mr.

Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023

SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2022 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced that Kintara had received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma, a rare and highly aggressive childhood brain cancer (December).

Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be presenting at the BIO CEO & Investor Conference on Monday, February 6, 2023.

Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference

SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. ( Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be presenting at the Biotech Showcase Conference in San Francisco.

Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023

Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.

Is Kintara Therapeutics A Hidden Gem?

Kintara Therapeutics Inc KTRA shares are trading higher by 24.09% to $9.94 Thursday morning after the company received FDA Orphan Drug Designation (ODD) for VAL-083.

Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday - Kintara Therapeutics (NASDAQ:KTRA)

SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and highly-aggressive childhood brain cancer. The FDA's ODD program provides orphan status to drugs defined as those intended for the treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people.

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

SAN DIEGO , Dec. 1, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market. The notice the Company received from Nasdaq on November 29, 2022 noted that the Company evidenced a closing bid price of its shares of common stock at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days.

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of patients with cutaneous metastatic breast cancer (CMBC). REM-001 was studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy.

Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from three posters that are being presented at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting. The 2022 SNO Annual Meeting is being held from November 16 through November 20, 2022 in Tampa, Florida.

Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it will effect a 1-for-50 reverse stock split of its outstanding and authorized common stock, effective at 5:00 p.m. (EST) on November 11, 2022.

Kintara Announces One-for-Fifty Reverse Stock Split

SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2022 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTS Paused the REM-001 program in Cutaneous Metastatic Breast Cancer (CMBC) to conserve cash which will be used to support the funding of the Company's ongoing international registrational study for VAL-083 in glioblastoma (GBM).

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

Microvast Holdings

RedHill Biopharma

SenesTech

Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Strategies for Buying and Selling Penny Stocks Right Now

REM-001 15-Patient Study Paused to Conserve Funds – Approximately $3 Million Saved through 2023 SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that the REM-001 program in Cutaneous Metastatic Breast Cancer (CMBC) was paused to conserve cash which will be used to support the funding of the Company's ongoing international registrational study for VAL-083 in glioblastoma (GBM). By pausing the REM-001 program, the Company expects to save approximately $3.0 million through 2023.

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

SAN DIEGO , Sept. 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2022 and provided a corporate update.

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update

SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that three posters have been accepted for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting.

Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin its 15 patient study evaluating REM-001 Photodynamic Therapy (PDT) for the treatment of Cutaneous Metastatic Breast Cancer (CMBC). This study is intended to aid in the design of a planned phase 3 registrational study.

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Under the terms of and subject to satisfaction of the conditions contained in the agreement, Kintara will have the right in its sole discretion, but not the obligation, to sell to LPC up to $20 million worth of shares of its common stock from time to time over the 36-month term of the agreement.

Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

SAN DIEGO , June 21, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference.

Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference

Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 28.6% to $0.24 after the FDA granted Fast Track Designation to the company's VAL-083. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an.

Why Kintara Therapeutics Shares Are Skyrocketing Today

BitNile Holdings

ThermoGenesis Holdings, Inc

There are over 500 Nasdaq & NYSE listed stocks, right, and warrants… The post 3 Red Hot Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Red Hot Penny Stocks Under $1 To Watch Before Next Week

SAN DIEGO , June 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's VAL-083 for the treatment of patients with newly-diagnosed unmethylated glioblastoma (GBM). Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma

Atossa Genetics

PHX Minerals

Here's what you need to know about buying penny stocks in 2022 The post Best Tips for Buying Penny Stocks in 2022? 3 to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Tips for Buying Penny Stocks in 2022? 3 to Know

SAN DIEGO , June 10, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the JMP Securities Life Sciences Conference.

News for Kintara Therapeutics Stock (KTRA)